CoChat

AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists

Open access
Fletcher, Madeleine M., Keov, Peter, Truong, Tin T., Mennen, Grace, Hick, Caroline A., Zhao, Peishen, Furness, Sebastian G.B., Kruse, Thomas, Clausen, Trine R., Wootten, Denise, Sexton, Patrick M. · 2021 · The Journal of Pharmacology and Experimental Therapeutics
Cited by 68

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Obesity and associated comorbidities are a major health burden, and novel therapeutics to help treat obesity are urgently needed. There is increasing evidence that targeting the amylin receptors (AMYRs), heterodimers of the calcitonin G protein-coupled receptor (CTR) and receptor activity-modifying proteins, improves weight control and has the potential to act additively with other treatments such as glucagon-like peptide-1 receptor agonists. Recent data indicate that AMYR agonists, which can also independently activate the CTR, may have improved efficacy for treating obesity, even though selective activation of CTRs is not efficacious. AM833 (cagrilintide) is a novel lipidated amylin analog that is undergoing clinical trials as a nonselective AMYR and CTR agonist. In the current study, we have investigated the pharmacology of AM833 across 25 endpoints and compared this peptide with AMYR selective and nonselective lipidated analogs (AM1213 and AM1784), and the clinically used peptide agonists pramlintide (AMYR selective) and salmon CT (nonselective). We also profiled human CT and rat amylin as prototypical selective agonists of CTR and AMYRs, respectively. Our results demonstrate that AM833 has a unique pharmacological profile across diverse measures of receptor binding, activation, and regulation. SIGNIFICANCE STATEMENT: AM833 is a novel nonselective agonist of calcitonin family receptors that has demonstrated efficacy for the treatment of obesity in phase 2 clinical trials. This study demonstrates that AM833 has a unique pharmacological profile across diverse measures of receptor binding, activation, and regulation when compared with other selective and nonselective calcitonin receptor and amylin receptor agonists. The present data provide mechanistic insight into the actions of AM833.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/jpet.121.000567

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 41

  1. Andreassen, 2014, A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats, Am J Physiol Endocrinol Metab, 307, E24, 10.1152/ajpendo.00121.2014 · DOI · Paper page
  2. Aronne, 2010, Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial, Obesity (Silver Spring), 18, 1739, 10.1038/oby.2009.478 · DOI · Paper page
  3. Chelikani, 2007, Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats, Am J Physiol Regul Integr Comp Physiol, 293, R1798, 10.1152/ajpregu.00386.2007 · DOI
  4. Dal Maso, 2018, Characterization of signalling and regulation of common calcitonin receptor splice variants and polymorphisms, Biochem Pharmacol, 148, 111, 10.1016/j.bcp.2017.12.016 · DOI
  5. Feigh, 2011, A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats, Diabetes Obes Metab, 13, 911, 10.1111/j.1463-1326.2011.01425.x · DOI · Paper page
  6. Feinstein, 2011, Retromer terminates the generation of cAMP by internalized PTH receptors, Nat Chem Biol, 7, 278, 10.1038/nchembio.545 · DOI · Paper page
  7. Ferrandon, 2009, Sustained cyclic AMP production by parathyroid hormone receptor endocytosis, Nat Chem Biol, 5, 734, 10.1038/nchembio.206 · DOI · Paper page
  8. Furness, 2016, Ligand-dependent modulation of g protein conformation alters drug efficacy, Cell, 167, 739, 10.1016/j.cell.2016.09.021 · DOI · Paper page
  9. Gingell, 2014, Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors, Endocrinology, 155, 21, 10.1210/en.2013-1658 · DOI · Paper page
  10. Gingell, 2020, Distinct patterns of internalization of different calcitonin gene-related peptide receptors, ACS Pharmacol Transl Sci, 3, 296, 10.1021/acsptsci.9b00089 · DOI
  11. Gorn, 1992, Cloning, characterization, and expression of a human calcitonin receptor from an ovarian carcinoma cell line, J Clin Invest, 90, 1726, 10.1172/JCI116046 · DOI · Paper page
  12. Guerreiro, 2013, Preparation and characterization of PEGylated amylin, AAPS PharmSciTech, 14, 1083, 10.1208/s12249-013-9987-4 · DOI
  13. Gydesen, 2016, KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight, Am J Physiol Endocrinol Metab, 310, E821, 10.1152/ajpendo.00514.2015 · DOI · Paper page
  14. Gydesen, 2017, Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog, Am J Physiol Endocrinol Metab, 313, E598, 10.1152/ajpendo.00419.2016 · DOI · Paper page
  15. Gydesen, 2017, A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference, Br J Pharmacol, 174, 591, 10.1111/bph.13723 · DOI · Paper page
  16. Hay, 2005, Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes, Mol Pharmacol, 67, 1655, 10.1124/mol.104.008615 · DOI · Paper page
  17. Iepsen, 2015, Liraglutide for Type 2 diabetes and obesity: a 2015 update, Expert Rev Cardiovasc Ther, 13, 753, 10.1586/14779072.2015.1054810 · DOI · Paper page
  18. Ismail, 2016, Internalized Receptor for Glucose-dependent Insulinotropic Peptide stimulates adenylyl cyclase on early endosomes, Biochem Pharmacol, 120, 33, 10.1016/j.bcp.2016.09.009 · DOI
  19. Kolterman, 1996, Effect of 14 days’ subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM, Diabetologia, 39, 492, 10.1007/BF00400683 · DOI
  20. Kowalczyk, 2014, Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism, Org Biomol Chem, 12, 8142, 10.1039/C4OB01208A · DOI · Paper page
  21. Larsen, 2019, The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy, J Pharmacol Exp Ther, 370, 35, 10.1124/jpet.119.257576 · DOI
  22. Larsen, 2020, The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy, J Pharmacol Exp Ther, 374, 74, 10.1124/jpet.119.263392 · DOI
  23. Larsen, 2020, Dose frequency optimization of the dual amylin and calcitonin receptor agonist KBP-088: long-lasting improvement in food preference and body weight loss, J Pharmacol Exp Ther, 373, 269, 10.1124/jpet.119.263400 · DOI
  24. Lutz, 2010, The role of amylin in the control of energy homeostasis, Am J Physiol Regul Integr Comp Physiol, 298, R1475, 10.1152/ajpregu.00703.2009 · DOI · Paper page
  25. Lutz, 2000, Amylin receptors mediate the anorectic action of salmon calcitonin (sCT), Peptides, 21, 233, 10.1016/S0196-9781(99)00208-9 · DOI
  26. Mack, 2011, Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide, Diabetes Obes Metab, 13, 1105, 10.1111/j.1463-1326.2011.01465.x · DOI · Paper page
  27. Mack, 2010, Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight, Int J Obes, 34, 385, 10.1038/ijo.2009.238 · DOI
  28. Mathiesen, 2021, Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat, Front Endocrinol (Lausanne), 11, 617400, 10.3389/fendo.2020.617400 · DOI
  29. Michelangeli, 1983, Mechanisms of calcitonin induction of prolonged activation of adenylate cyclase in human cancer cells, J Cyclic Nucleotide Protein Phosphor Res, 9, 129
  30. Motulsky, 1984, The kinetics of competitive radioligand binding predicted by the law of mass action, Mol Pharmacol, 25, 1, 10.1016/S0026-895X(25)15016-5 · DOI · Paper page
  31. Namkung, 2016, Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET, Nat Commun, 7, 12178, 10.1038/ncomms12178 · DOI · Paper page
  32. Olsen, 2020, TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome, Nat Chem Biol, 16, 841, 10.1038/s41589-020-0535-8 · DOI · Paper page
  33. Qi, 2013, Receptor activity-modifying protein-dependent impairment of calcitonin receptor splice variant Δ(1-47)hCT((a)) function, Br J Pharmacol, 168, 644, 10.1111/j.1476-5381.2012.02197.x · DOI · Paper page
  34. Ravussin, 2009, Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy, Obesity (Silver Spring), 17, 1736, 10.1038/oby.2009.184 · DOI · Paper page
  35. Srivastava, 2018, Current pharmacotherapy for obesity, Nat Rev Endocrinol, 14, 12, 10.1038/nrendo.2017.122 · DOI · Paper page
  36. Tomabechi, 2013, Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists, Chemistry, 19, 15084, 10.1002/chem.201303303 · DOI · Paper page
  37. Udawela, 2006, A critical role for the short intracellular C terminus in receptor activity-modifying protein function, Mol Pharmacol, 70, 1750, 10.1124/mol.106.024257 · DOI
  38. Udawela, 2006, Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors, Mol Pharmacol, 69, 1984, 10.1124/mol.105.021915 · DOI
  39. Wells, 2016, Does salmon calcitonin cause cancer? A review and meta-analysis, Osteoporos Int, 27, 13, 10.1007/s00198-015-3339-z · DOI · Paper page
  40. Young, 1996, Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin, Drug Dev Res, 37, 231, 10.1002/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M · DOI · Paper page
  41. Zakariassen, 2020, Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice, Neuropharmacology, 167, 107987, 10.1016/j.neuropharm.2020.107987 · DOI · Paper page

Cited by

See all 68

Metadata

Authors
Fletcher, M. M., Keov, P., Truong, T. T., Mennen, G., Hick, C. A., Zhao, P., Furness, S. G. B., Kruse, T., Clausen, T. R., Wootten, D., & Sexton, P. M.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2021-06
Volume
377
Issue
3
Pages
417-440
ISSN
0022-3565 (ISSN-L)
OpenAlex
W3138702158
Cited by
68
References
13
FWCI
3.32
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. https://app.cochat.ai/papers/10.1124/jpet.121.000567
The paper
Fletcher, M. M., Keov, P., Truong, T. T., Mennen, G., Hick, C. A., Zhao, P., Furness, S. G. B., Kruse, T., Clausen, T. R., Wootten, D., & Sexton, P. M. (2021). AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.121.000567

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.